Traders assign a 91.5% probability to no new COVID variant of concern before 2027 because SARS-CoV-2 continues to circulate primarily through Omicron sublineages such as XFG and NB.1.8.1 without meeting World Health Organization criteria for elevated transmissibility, immune escape, or severity. As of mid-2026, global surveillance from WHO and ECDC lists only variants under monitoring, with the most recent designations like BA.3.2 and PQ.16.1.1 remaining in lower-risk categories despite localized increases in detections during late 2025 and early 2026. Low overall case rates, stable hospital data, and vaccine updates targeting recent lineages further support this trader consensus, reflecting limited evidence of a disruptive shift in the coming months.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoSì
$245,006 Vol.
$245,006 Vol.
Sì
$245,006 Vol.
$245,006 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercato aperto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Traders assign a 91.5% probability to no new COVID variant of concern before 2027 because SARS-CoV-2 continues to circulate primarily through Omicron sublineages such as XFG and NB.1.8.1 without meeting World Health Organization criteria for elevated transmissibility, immune escape, or severity. As of mid-2026, global surveillance from WHO and ECDC lists only variants under monitoring, with the most recent designations like BA.3.2 and PQ.16.1.1 remaining in lower-risk categories despite localized increases in detections during late 2025 and early 2026. Low overall case rates, stable hospital data, and vaccine updates targeting recent lineages further support this trader consensus, reflecting limited evidence of a disruptive shift in the coming months.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti